Elben
Zhao Qing Longda Biotechnology Co. Ltd.
No. 20 Yingbin Road
Gaoxin District
Zhaoqing Shi
Guangdong Sheng , 526238
China
2112257989@qq.comFEI 3014354419Issued Sep 18, 2023Center for Drug Evaluation and Research | CDER
Source: FDA, published letter. FDA published this warning letter; View Letter opens FDA's copy. To check it, open FDA's record for this establishment, listed under FEI 3014354419.
Violations1
Issue DateSep 18, 2023
Product TypeOther
StatusOpen
Letter Details
Firm
Zhao Qing Longda Biotechnology Co. Ltd.
Location
Elben
Zhao Qing Longda Biotechnology Co. Ltd.
No. 20 Yingbin Road
Gaoxin District
Zhaoqing Shi
Guangdong Sheng , 526238
China
2112257989@qq.com
FEI Number
3014354419
Country
China
Issue Date
September 18, 2023
Issuing Office
Center for Drug Evaluation and Research | CDER
Product Type
Other
Status
Open
Summary
Zhao Qing Longda Biotechnology Co. Ltd., a Chinese manufacturer of over-the-counter drug products including children's toothpaste, refused to provide access to records and information requested by the FDA pursuant to section 704(a)(4) of the Federal Food, Drug, and Cosmetic Act. The company explicitly stated on April 19, 2023, that it was "not prepared to allow the FDA to audit and inspect" its firm, despite multiple requests sent via email on March 17, April 6, and April 18, 2023, and a follow-up written request on April 28, 2023. This refusal violated section 301(e) of the FD&C Act, which prohibits refusing to permit access to or copying of required records. The FDA's inspection was prompted by concerns regarding potential contamination of the company's drug ingredients—particularly those susceptible to diethylene glycol and ethylene glycol substitution—which have caused lethal poisoning incidents globally.
Zhao Qing Longda Biotechnology Co. Ltd. FDA Warning Letter, September 18, 2023